Anti-GATA3 monoclonal antibody, clone 8C6

Breast cancer patients at the same stage may show different clinical prognoses or different therapeutic effects of systemic therapy: Differentially expressed genes of breast cancer were identified from GSE42568. Through survival, receiver operating, characteristic (ROC) curve, random forest, GSVA and a Cox regression model analyses, genes were identified that could be associated with survival time in breast cancer. The molecular mechanism was identified by enrichment, GSEA, methylation and !..;NV analyses. Then, the expression of a key gene was verified by the TCGA data et and RT-ciPCR, Western blot, and immunohistochemistry. V:e identified :784 genes related to the 5-year overall survival time of breast cancer. Through ROC curve and random forest analysis, 10 prognostic genes were screened. These were integrated into a complex by GSVA, and high expression of the comrlex significantly promoted the recurrence-free survival of patients. In addition, key genes were related to immune and metabolic-related functions. Importantly, we identified methylation of MEX3A and TBC1D 9 and mutations events. Finally, the expression of UGCG was verified by the TCGA dataset and by experimental methods in our own samples. These results indicate that 10 genes may be potential biomarkers and therapeutic targets for long-term survival in breast cancer, especially UGCG.

The escape of cancer cells from host immunosurveillance involves a shift in immune responses, including an imbalance in Th1 and Th2 cells. A Th1-dominated immune response predicts positive outcomes in colorectal cancer. The E3 ubiquitin ligase, Asb2 alpha, is expressed in Th2 cells, but its roles in T-cell maturation and cancer are unclear. We provide evidence that the Th2 master regulator, Gata3, induces Asb2. Loss of Asb2 did not affect Th differentiation ex vivo, but reduced IL4 production from Th2 cells. We found that high ASB2 expression was associated with poor outcome in colorectal cancer. Loss of Asb2 from hematopoietic cells promoted a Th1 response and attenuated colitis-associated tumorigenesis in mice. Diminished Th2 function correlated with increased IFN gamma production and an enhanced type 1 antitumor immune response in Asb2-deficient mice. Our work suggests that Asb2 alpha promotes a Th2 phenotype in vivo, which in turn is associated with tumor progression in a mouse model of colitis.